Synthesis and serotonergic activity of substituted 2,N- benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N,N-dimethyltryptamine derivatives: Novel antagonists for the vascular 5-HT(1B)-like receptor

Journal of Medicinal Chemistry

Volumn 42, Issue 14, 1999, Pages 2504-2526

  Moloney, Gerard P ^a   Martin, Graeme R ^b   Mathews, Neil ^c   Milne, Aynsley ^c   Hobbs, Heather ^c   Dodsworth, Susan ^c   Sang, Pang Yih ^c   Knight, Cameron ^a   Williams, Marnie ^a   Maxwell, Miles ^c   Glen, Robert C ^d  

^a MONASH UNIVERSITY   (Australia)

^b ROCHE BIOSCIENCE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d TRIPOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N BENZYL 3 [2 (DIMETHYLAMINO)ETHYL] 5 [2 (4,4 DIMETHYL 2,5 DIOXO 1 IMIDAZOLIDINYL)ETHYL] 1H INDOLE 2 CARBOXAMIDE; SEROTONIN 1B ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMORAL ARTERY; NONHUMAN; RABBIT;

ANIMALS; AORTA, THORACIC; BINDING, COMPETITIVE; CEREBRAL CORTEX; DOGS; FEMORAL ARTERY; IMIDAZOLES; INDOLES; MODELS, MOLECULAR; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SAPHENOUS VEIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRACHEA;

EID: 0033566088     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9706325     Document Type: Article

References (46)

1. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46, 157-204.
2. Martin, G. R.; Humphrey, P. P. A. Receptors for 5-Hydroxy Tryptamine: Current Perspectives on Classification and Nomenclature. Neuropharmacology 1994, 33, 261-273.
3. Hoyer, D.; Martin, G. R. 5-HT Receptor Classification and Nomenclature: Towards a Harmonisation with the Human Genome. Neuropharmacology 1997, 36, 419-428.
4. Vanhoutte, P. M.; Humphrey, P. P. A.; Spedding, M. Recommendations for Nomenclature of New Receptor Subtypes. Pharmacol. Rev. 1996, 48, 1-2.
5. 1D Receptor Subtypes. Trends Pharmacol. Sci. 1996, 17, 103-105.
6. 1-like Receptor in Dog Isolated Saphenous Vein. Br. J. Pharmacol. 1988, 94, 1123-1132.
7. Dechant, K. L.; Clissold, S. P. Sumatriptan. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache. Drugs 1992, 43, 776-798.
8. North, P. C. Migraine Therapy - Serotonin to Sumatriptan. In Medicinal Chemistry: Principles and Practice; King, F. G., Ed.; The Royal Society of Chemistry: London, 1994.
9. 1D Agents for the Acute Treatment of Migraine Headache. Headache 1994, 34, 307.
10. 1D Receptors: Pharmacology and Therapeutic Potential. Serotonin ID Res. Alert 1996, 1, 19-29.
11. Martin, G. R. Serotonin Receptor Involvement in the Pathogenesis and Treatment of Migraine. In Blue Books on Neurology; Silberstein, S., Goadsby, P. J., Eds.
12. (a) European Patent EP 0 533 266 A1, 1992.
13. (b) European Patent EP 0 533 267 A1, 1992.
14. (c) European Patent EP 0 533 268 A1, 1992.
15. 1D Antagonists. J. Med. Chem. 1994, 37, 2253-2257.
16. 1D Receptor Antagonist GR127935 on Extracellular Levels of 5-HT in the Guinea- pig Frontal Cortex as Measured by Microdialysis. Neuropharmacology 1995, 34, 377-382.
17. 1Dβ Receptors. Eur. J. Pharmacol. 1995, 287, 79-84.
18. McFadden, E. P.; Clarke, J. G.; Davies, G. J.; Kaski, J. C.; Haider, A. W.; Maseri, A. Effect of Intracoronary Serotonin on Coronary Vessels in Patients with Stable Angina and Patients with Variant Angina. N. Engl. J. Med. 1991, 324, 648-654.
19. Golino, P.; Piscione, F.; Willerson, J. T.; Cappelli-Bigazzi, M.; Focaccio, A.; Villari, B.; Indolfi, C.; Russolillo, E.; Condorelli, M.; Chiariello, M. Divergent Effects of Serotonin on Coronary Artery Dimensions and Blood Flow in Patients with Coronary Atherosclerosis and Control Patients. N. Engl. J. Med. 1991, 324, 641-648.
20. Maseri, A. Pathogenetic Components of Acute Ischemic Syndromes. Focus on Acute Ischemic Stimuli. Circulation 1990, I1-I3.
21. Fitzgerald, D. J.; Roy, L.; Catella, F.; Fitzgerald, G. A. Platelet Activation in Unstable Coronary Disease. N. Engl. J. Med. 1986, 315, 983-989.
22. Bradley, P. B.; Engel, G.; Feniuk, W.; Fozard, J. R.; Humphrey, P. P. A.; Middlemiss, D. N.; Mylecharane, E. J.; Richardson, B. P.; Saxena, P. R. Proposals for the Classification and Nomenclature of Functional Receptors for 5-Hydroxytryptamine. Neuropharmacology 1986, 25, 563-576.
23. Scherbel, A. L.; Harrison, J. N. Response to Serotonin and its Antagonists in Patients with Rheumatoid Arthritis and Related Diseases. Angiology 1959, 10, 29-38.
24. 1B/1D Receptor Antagonists. J. Med. Chem. 1997, 40, 2347-2362.
25. Phillips, R. R. The Japp-Klingemann Reaction. Org. React. 1959, 10, 143-178.
26. Japp, F. R.; Klingemann, P. Methoden der organischen Chemie; Houben-Weyl-Muller; Board X/3, S.523; Thieme-Verlag: Stuttgart, 1965.
27. Robinson, B. The Fisher Indole Synthesis; John Wiley and Sons: New York, 1982.
28. (a) Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of natural Products. Synthesis 1981, 1-28.
29. (b) Hughes, D. L. The Mitsunobu Reaction. Org. React. 1992, 42, 335-656.
30. (a) Koppel, I.; Koppel, J.; Degerbeck, F.; Grehn, L.; Ragnarsson, U. Acidity of Imidocarbonates and Tosylcarbamates in Dimethyl sulfoxide. Correlation with Yields in the Mitsunobu Reaction. J. Org. Chem. 1991, 56, 7172-7174.
31. (b) Henry, J. R.; Marcin, L. R.; McIntosh, M. C.; Scola, P. M.; Harris, G. D., Jr.; Weinreb, S. M. Mitsunobu Reactions of N-Alkyl and N-Acyl Sulfonamides-An Efficient Route to Protected Amines. Tetrahedron Lett. 1989, 30, 5709-5712.
32. (c) Mitsunobu, O.; Wada, M.; Sano, T. Stereospecific and Stereoselective Reactions. I. Preparation of Amines from Alcohols. J. Am. Chem. Soc. 1972, 94, 679-680.
33. 1D Receptor: Discovery of Compounds with Potential Anti-Migraine Properties. J. Med. Chem. 1995, 38, 3566-3580.
34. (a) Oxford, A. W.; Mitchell, W. L.; Bradshaw, J.; Clitherow, J. W. Glaxo Group Ltd. European Patent EP 0 533 266 A1, 1992.
35. (b) European Patent EP 0 533 267 A1, 1992.
36. (c) European Patent EP 0 533 268 A1, 1992.
37. Sybyl 6.1, molecular modeling package; Tripos Associates, St. Louis, MO 63144; 1992.
38. Brieskorn, C. H.; Wittig G. Synthesis of Derivatives of Indoles, Diindolylmethanes and Indolyl(tetrahydroindolyl)methanes. Arch. Pharm. (Weinheim) 1978, 311, 954-960.
39. Ksander, G. M.; McMurray, J. E.; Johnson, M. A Method for the Synthesis of Unsaturated Carbonyl Compounds. J. Org. Chem. 1977, 42, 1180-1185.
40. Ohler, E.; Schmidt, U. Hydroxylsubstituierte Cyclodipeptide durch Ringschluss von Pyruvoylamino Säureamiden, II. Chem. Ber. 1975, 108, 2907-2916.
41. Martin, G. R.; MacLennan, S. J. Analysis of the 5-HT Receptor in Rabbit Saphenous Vein Exemplifies the Problems of Using Exclusion Criteria for Receptor Classification. Naunyn-Schmiedebergs Arch. Pharmacol. 1990, 342, 111-119.
42. 2 receptor-mediated contraction of the rabbit isolated femoral artery. Br. J. Pharmacol. 1992, 107, 418-421.
43. Leff, P. An analysis of amplifying and potentiating interactions between agonists. J. Pharmacol. Exp. Ther. 1987, 243, 1035-1042.
44. 2 receptors: A problem of acute desensitization? Br. J. Pharmacol. 1988, 95, 569-577.
45. Glen, R. C.; Martin, G. R.; Hill, A. P.; Hyde, R. M.; Woollard, P. M.; Salmon, J. A.; Buckingham, J.; Robertson, A. D. J. Med. Chem. 1995, 38, 3566-3580.
46. Woolard, P.; Salmon, J. A. Unpublished results.